Dermal Substitution in Pediatric Burns
Launched by RADBOUD UNIVERSITY MEDICAL CENTER · Mar 24, 2022
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how a special skin substitute, called Glyaderm, can help improve the healing of serious burns in children. When kids suffer deep burns, doctors usually remove the damaged skin and then cover the area with a skin graft. Glyaderm is designed to replace some of the skin layers that are lost, potentially leading to better scars that feel softer and more elastic. The study aims to see how well Glyaderm works specifically for kids aged 15 and younger who have deep burns that need skin grafting.
To be eligible for this trial, children must be 15 years old or younger and have burn wounds that are large enough to require a skin graft. Parents or guardians will need to give their permission, and older children (ages 12-15) will also need to agree to participate. It's important to note that children with very small burns, infected wounds, or language barriers that prevent them from understanding the study won't be included. Participants will have regular check-ups to monitor how their scars heal, and the information gathered will help researchers understand the benefits of using Glyaderm in treating burns in children.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Age ≤15 years old
- • 2. Burn wounds requiring skin grafting
- • 3. Written informed consent provided by
- • 1. The participant's parent(s)/guardian (\<12 years of age)
- • 2. The participant's parent(s)/guardian and the participant itself (12-15 years old)
- Exclusion Criteria:
- • 1. Burn wound of ≤30 cm2
- • 2. Infected burn wounds: clinical symptoms in combination with positive wound swabs
- • 3. Patients/parents with insufficient knowledge of the Dutch or English language, since they would not be able to complete the POSAS questionnaire.
About Radboud University Medical Center
Radboud University Medical Center is a leading academic medical institution located in Nijmegen, the Netherlands, dedicated to advancing healthcare through innovative research and education. As a prominent sponsor of clinical trials, Radboud UMC leverages its multidisciplinary expertise to conduct high-quality research that aims to improve patient outcomes and enhance medical knowledge. The center is committed to ethical standards and regulatory compliance, fostering collaboration among researchers, healthcare professionals, and patients to translate scientific discoveries into effective clinical applications. With a focus on personalized medicine and cutting-edge technologies, Radboud University Medical Center plays a pivotal role in shaping the future of healthcare through its rigorous clinical trial initiatives.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Nijmegen, , Netherlands
Patients applied
Trial Officials
Marielle Vehmeijer-Heeman, MD, PhD
Principal Investigator
Radboud University Medical Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials